Home > Boards > US OTC > Delisted > Endologix Inc. (fka ELGXQ)

8:33AM Endologix announces presentation of data From PEVAR

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
surf1944 Member Profile
 
Followed By 437
Posts 25,764
Boards Moderated 5
Alias Born 09/11/06
160x600 placeholder
North American Rail Traffic Rose 2.6% in Week Ended Oct. 17
North American rail traffic rose 2.6% last week for a third straight weekly increase, powered by double-digit gains in intermodal volume in the U.S. and Canada, data from the Association of American Railroads showed.
Gilead Sciences On Pace for Lowest Close Since October 2013 -- Data Talk
Correction to Wall Street Electric Car Article
Vinci Subsidiary Gets Two Contracts for New Zealand Rail for About EUR485 Million
UniCredit Sells Italian Non-Performing Loans Portfolio to Illimity Bank
Treasury Yields Touch Multi-month Highs
U.S. Stocks Lower As Stimulus Talks Continue
T-Mobile Starts VC Fund for 5G
Europe's Antitrust Push Against Google Hasn't Dented Its Heft. Can the U.S.?
AT&T On Pace for 10-Day Losing Streak -- Data Talk
Judge in Google Lawsuit Presided Over Major Antitrust Case
HSBC to Cut Up to 300 UK Commercial Banking Jobs -Reuters
Nestle's Organic Sales Growth Beat Consensus -- Earnings Review
Top Company News of the Day
Why Central Banks Want to Create Their Own Digital Currencies Like Bitcoin
U.S. Stocks Climb Amid Stimulus Hopes, Earnings
Thermo Fisher Scientific Expects 2020 Revenue to Grow 20%
Form 8.3 - Willis Towers Watson Plc.
Why People Are Still Obsessed With 'Candy Crush Saga' -- Journal Report
Housing Starts and Existing Home Sales Seen Rising -- Data Week Ahead
Open-Source Startup Anyscale Raises $40 Million in Series B Funding Round
HSBC Hires Former Credit Suisse Deal Maker for Vice-Chair Role -- Financial News
surf1944   Monday, 01/28/13 10:49:37 AM
Re: surf1944 post# 5
Post # of 66 
8:33AM Endologix announces presentation of data From PEVAR randomized trial; 94% procedural technical success rate; 'significantly' reduced procedure times and time to hemostasis (ELGX) 15.63 : Co announced that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) was recently presented at two medical meetings. Key points from the trial include:

The primary trial endpoint was met (P<.0036), definitively demonstrating the non-inferiority of PEVAR using the ProGlide closure device to surgical EVAR
A 94% procedural technical success rate was achieved in a multicenter setting
Mean procedure time was reduced in PEVAR patients by 34 minutes (P=.006). Likewise, mean time to hemostasis was reduced following PEVAR by 13 minutes (P=.002)
PEVAR patients required significantly fewer concomitant procedures
Favorable trending of PEVAR in several clinical utility outcomes including reduced anesthesia time, reduced blood loss and need for transfusion, shorter hospital length of stay, and less analgesics prescribed for groin pain
The PEVAR non-inferiority to surgical EVAR persisted through the final 6-month follow-up

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences